Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord. SE CONNECTER À UN COMPTE LECTEUR CRÉER UN COMPTE LECTEUR
PaxMedica Holds Meeting of Scientific Advisory Board
20 mars 2023 08h00 HE
|
PaxMedica, Inc.
Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S. TARRYTOWN, NY, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical...
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
14 mars 2023 16h30 HE
|
Affimed N.V.
An oral presentation on the safety and efficacy from the AFM13 phase 2 monotherapy clinical study (“REDIRECT”) in patients with CD30-positive relapsed or refractory (R/R) peripheral T-cell lymphoma...
Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering
14 mars 2023 08h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing
11 mars 2023 07h00 HE
|
Cytovance Biologics
OKLAHOMA CITY, March 11, 2023 (GLOBE NEWSWIRE) -- Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract development and manufacturing organization (CDMO), and Phenotypeca...
Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
09 mars 2023 16h05 HE
|
Clearside Biomedical, Inc.
- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety...
Clinical Trials Support Services Market Value to Reach US$ 48.5 Bn by 2033, as per TMR Report
08 mars 2023 12h00 HE
|
Transparency Market Research
Wilmington, Delaware, United States, March 08, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. – The global Clinical Trials Support Services Market is projected to expand at a CAGR of...
MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
07 mars 2023 08h00 HE
|
MBX Biosciences, Inc.
CARMEL, Ind., March 07, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of...
IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes
03 mars 2023 14h07 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO...
Syneos Health Reports Fourth Quarter and Full Year 2022 Results
16 févr. 2023 06h03 HE
|
Syneos Health, Inc.
Revenue for the fourth quarter of $1,359.9 million decreased 1.0% on a reported basis and increased 1.7% on a constant currency basis year-over-year.Clinical Solutions net new business awards and...
PaxMedica Releases 2022 Shareholder Letter
15 févr. 2023 07h30 HE
|
PaxMedica, Inc.
Company Anticipates Multiple Milestones in Next 12-24 Months TARRYTOWN, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage...